Aurobindo Pharma Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
46,455
- Stock Symbol
-
AUROPHARMA
- Investments
-
24
- Share Price
-
$19.32
- (As of Thursday Closing)
Aurobindo Pharma General Information
Description
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are: India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
Contact Information
Website
www.aurobindo.comCorporate Office
- Galaxy, Floors 22-24, Plot No.1, Survey Number 83/1
- Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District
- Hyderabad, Telangana 500032
- India
Corporate Office
- Galaxy, Floors 22-24, Plot No.1, Survey Number 83/1
- Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District
- Hyderabad, Telangana 500032
- India
Aurobindo Pharma Stock Performance
As of 19-Nov-2026, Aurobindo Pharma’s stock price is $19.32. Its current market cap is $11.1B with 575M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $19.32 | $19.22 | $12.17 - $19.80 | $11.1B | 575M | 983K | $0.74 |
Aurobindo Pharma Financials Summary
As of 30-Sep-2026, Aurobindo Pharma has a trailing 12-month revenue of $3.96B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 9,754,018 | 7,852,671 | 7,971,640 | 7,558,455 |
| Revenue | 3,957,021 | 3,778,104 | 3,710,875 | 3,467,320 |
| EBITDA | 881,209 | 780,380 | 797,642 | 707,153 |
| Net Income | 430,354 | 396,628 | 412,251 | 383,274 |
| Total Assets | 6,429,310 | 6,200,375 | 5,820,128 | 5,404,679 |
| Total Debt | 898,455 | 855,603 | 965,974 | 797,140 |
Aurobindo Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aurobindo Pharma Comparisons
Industry
Financing
Details
Aurobindo Pharma Competitors (35)
One of Aurobindo Pharma’s 35 competitors is Glenmark Pharmaceuticals, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Wockhardt | Corporation | Mumbai, India | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Alkem Laboratories | Formerly PE-Backed | Mumbai, India |
Aurobindo Pharma Patents
Aurobindo Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240358695-A1 | Pharmaceutical compositions of rimegepant | Pending | 25-Apr-2023 | ||
| US-20240285618-A1 | Pharmaceutical compositions of lumateperone | Pending | 20-Feb-2023 | ||
| WO-2024171021-A1 | A process for the preparation of belumosudil and its | Inactive | 13-Feb-2023 | ||
| WO-2024134368-A1 | Solid state form of mavacamten | Inactive | 23-Dec-2022 | ||
| US-20230390254-A1 | Pharmaceutical compositions of ubrogepant and process for preparation thereof | Inactive | 03-Jun-2022 | A61K31/437 |
Aurobindo Pharma Signals
Aurobindo Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aurobindo Pharma Investments & Acquisitions (24)
Aurobindo Pharma’s most recent deal was a Corporate with Swarnaaskshu Solar Power. The deal was made on 30-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Swarnaaskshu Solar Power | 30-Jun-2026 | Corporate | Energy Production | ||
| Swarnaakshu Solar Power | 25-Jun-2026 | Corporate | Energy Production | ||
| Garuda Renewables | 09-Feb-2026 | Secondary Transaction - Private | Energy Production | ||
| Khandelwal Laboratories (Non-Oncology prescription formulations business) | 01-Jan-2026 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| GLS Pharma | 25-Oct-2024 | Secondary Transaction - Private | Pharmaceuticals |
Aurobindo Pharma ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
28.62 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Aurobindo Pharma Exits (3)
Aurobindo Pharma’s most recent exit was on 07-Nov-2020 from Eugia Pharma Specialities. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Eugia Pharma Specialities | 07-Nov-2020 | Completed |
|
||
| Natrol | 09-Dec-2014 | Completed |
|
||
| Eugia Pharma Specialities | 17-Apr-2013 | Joint Venture | Completed |
|
Aurobindo Pharma Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Tergene Biotech | Hyderabad, India | 2010 | |
| GLS Pharma | New Delhi, India | 2004 | |
| AXIS Clinicals | Hyderabad, India | 2004 | |
| Generis Farmacêutica | Amadora, Portugal | 2002 | |
| Arrow Génériques | Lyon, France | 2000 |
Aurobindo Pharma FAQs
-
When was Aurobindo Pharma founded?
Aurobindo Pharma was founded in 1986.
-
Where is Aurobindo Pharma headquartered?
Aurobindo Pharma is headquartered in Hyderabad, India.
-
What is the size of Aurobindo Pharma?
Aurobindo Pharma has 46,455 total employees.
-
What industry is Aurobindo Pharma in?
Aurobindo Pharma’s primary industry is Pharmaceuticals.
-
Is Aurobindo Pharma a private or public company?
Aurobindo Pharma is a Public company.
-
What is Aurobindo Pharma’s stock symbol?
The ticker symbol for Aurobindo Pharma is AUROPHARMA.
-
What is the current stock price of Aurobindo Pharma?
As of 19-Nov-2026 the stock price of Aurobindo Pharma is $19.32.
-
What is the current market cap of Aurobindo Pharma?
The current market capitalization of Aurobindo Pharma is $11.1B.
-
What is Aurobindo Pharma’s current revenue?
The trailing twelve month revenue for Aurobindo Pharma is $3.96B.
-
Who are Aurobindo Pharma’s competitors?
Glenmark Pharmaceuticals, Wockhardt, Teva Pharmaceutical Industries, GSK, and Alkem Laboratories are some of the 35 competitors of Aurobindo Pharma.
-
What is Aurobindo Pharma’s annual earnings per share (EPS)?
Aurobindo Pharma’s EPS for 12 months was $0.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process